Investing

Relay Therapeutics : RLAY

RLAY

Stock Data

$12.87

$0.15 (1.18%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Relay Therapeutics is a pioneering company in the field of precision medicine, focusing on the development of small molecule therapies for cancer and genetic diseases. With a robust pipeline, including RLY-4008 targeting FGFR2 in solid tumors and RLY-2608 aimed at mutant-PI3Ka, Relay Therapeutics is at the forefront of utilizing computational modeling to revolutionize drug discovery. Additionally, its collaboration with Genentech on Migoprotafib highlights its commitment to advancing treatment options for patients with challenging diseases. Founded in 2015 and based in Cambridge, Massachusetts, Relay Therapeutics combines cutting-edge science with strategic partnerships to tackle unmet medical needs.

All Relay Therapeutics Articles

1 Article

Alex Sirois | 1 hour ago

Buy These 3 Clinical-Stage Biotechs Under $30 With Solid Cash Runways

Clinical-stage biotech is one of the few corners of the market where a sub-$30 share price genuinely matters: small-cap oncology…